Advanced Prostate Cancer VL

Mark Emberton on Focal therapy for men with intermediate risk prostate cancer and a solitary lesion should be standard of care - STOP 6

Details
Focal therapy for men with intermediate risk prostate cancer and a solitary lesion should be standard of care (STOP 6) Biography: Mark Emberton, MD, FRCS is a Professor of Interventional Oncology at the University College London. He is an Honorary Consultant Urologist at University College Hospitals NHS Foundation Trust and Founding Pioneer of The Charity Prostate Cancer UK. Dr. Emberton was appoi...

Journal Club: Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormones Agonist and an Antagonist

Details
Thomas Keane provides a journal club review on the article, "Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormones Agonist and an Antagonist", published in the European Association of Urology. The hypothesis and approach for this article includes a discussion around if a GnRH antagonist produce the same risk of cardiovascular complication when compared to an LHRH agonist. Also,...

Journal Club Review: Pharmacokinetic Aspects of the Two Novel Oral Drugs - Charles Ryan

Details
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide Guillemette E. Benoist, Rianne J. Hendricks, Peter F. A. Mulders, Winald R. Gerritsen, Diederik M. Somford, Jack A. Schalken, Inge M. van Oort, David M. Burger, Nielka P. van Erp In this Journal Club presentation, Dr. Charles Ryan's key points include h...

Role of the Gonadotrophin-Releasing Hormone Antagonists and Advanced Hormone-Dependent Prostate Cancer - Journal review

Details
This edition of Keane’s Corner is a Journal Club discussion on the article, “The Role of the Gonadotrophin-Releasing Hormone Antagonists in the Treatment of Patients with Advanced Hormone-Dependent Prostate Cancer in the UK”, published in the World Journal of Urology. Authors: Derek J. Rosario, Patrick Davey, James Green, Damien Greene, Bruce Turner, Heather Payne and Mike Kirby An overview of the...

Assessment of Cardiovascular Risk with the Use of Androgen Deprivation Therapy for Prostate Cancer - Matthew Roe

Details
UroToday is excited to host a lecture from a leading cardiologist’s perspective, Dr. Matthew Roe from Duke Clinical Research Institute. Dr. Roe’s discussion features the topics: atherosclerotic plaque formation and plaque instability and incidences of prostate cancer and cardiovascular events. In addition, cardiovascular risks with androgen deprivation therapy, GNRH antagonists and GnRH agonists....

Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer

Details
A journal club article review presented by Thomas Keane, MD. “Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients with Prostate Cancer”. Written by: Nirmanmoh Bhatia, Marilia Santos, Lee W. Jones, Joshua A. Beckman, David F. Penson, Alicia K. Morgans and Javid Moslehi In this presentation of the journ...

The understanding of personalized androgen deprivation therapy

Details
Thomas Keane, MD provides a presentation concerning the personalization of androgen deprivation with reference to prostate cancer patients. The discussion includes recent data that elevates the discussion on the impact of the agonist or the antagonist used in ADT for men with cardiac conditions, obesity, significant LUTS, and closes on an algorithm for personalized ADT treatment. Biography: Thomas...

Outpatient Urologic Oncology: Primer for the Advanced Practice Provider - Anne Calvaresi

Details
Outpatient Urologic Oncology: Primer for the Advanced Practice Provider In this video lecture Anne E Calvaresi, CRNP reviews all Outpatient Urologic Oncology Practice information used in the practices at Jefferson Urology Associates, in Philadelphia, PA. She reviews prostate cancer and bladder cancer in the outpatient setting focusing on the role of the advanced practice professional (NP/PA) and t...

E. David Crawford and Neal Shore - A Conversation on the Role of Chemotherapy in mHSPCa Patients

Details
An interview by E. David Crawford, MD with Neal Shore, MD discussing the role of early chemotherapy use in the treatment of metastatic hormone-sensitive men with prostate cancer. Neal Shore discusses the implications of CHAARTED and more recently STAMPEDE results that provide evidence supporting aggressively treating metastatic hormone-sensitive prostate cancer with docetaxel added to androgen dep...

A Review of Recent Data on Disease-related Outcomes Comparing Agonists and Antagonists for ADT - Thomas Keane

Details
A Review of Recent Data on Disease-related Outcomes Comparing Agonists and Antagonists for ADT Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator o...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe